Enhancing catchment area tools: A de-identification method for integrating clinical trial data with Cancer InFocus
Open Access
- 17 August 2024
- journal article
- Published by Taylor & Francis in Preventive Oncology & Epidemiology
- Vol. 2 (1)
Abstract
National Cancer Institute (NCI) designated cancer centers are entrusted with assessing the cancer burden within their catchment areas and using this information to guide research and outreach efforts. Data visualizations, like Cancer InFocus, have emerged as essential tools for facilitating this effort. Integrating clinical trial accrual data can further enhance our understanding of the catchment area. However, these data must be de-identified in accordance with the Health Insurance Portability and Accountability Act (HIPAA). This study introduces a de-identification method through geographic aggregation, ensuring HIPAA compliance and enabling comprehensive catchment area surveillance. Home addresses of patients enrolled in clinical trials at an NCI-designated Comprehensive Cancer Center were geocoded to census tracts. Tracts with less than 20 accruals were merged using the R geographic aggregation tool. A risk assessment was conducted to ensure low re-identification risk. Accrual rates were calculated and integrated into Cancer InFocus. Successful aggregation exceeded the 20-patient threshold for all merged tracts with low re-identification risk. Disparities between clinical trial accruals and social determinants of health were identified. The geographic aggregation method, compliant with HIPAA standards and integrated with Cancer InFocus, can enhance catchment area surveillance, furthering cancer research and outreach by pinpointing area-specific needs.Keywords
Funding Information
- National Cancer Institute (P20CA233304)
This publication has 18 references indexed in Scilit:
- Effects of socioeconomic status on enrollment in clinical trials for cancer: A systematic reviewCancer Medicine, 2024
- Developing Geographic Areas for Cancer Reporting Using Automated Zone DesignAmerican Journal of Epidemiology, 2022
- Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromesCancer, 2020
- The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollmentJournal of Neuro-Oncology, 2020
- Overcoming Barriers: Evidence-Based Strategies to Increase Enrollment of Underrepresented Populations in Cancer Therapeutic Clinical Trials—a Narrative ReviewJournal of Cancer Education, 2019
- The Population Burden of Cancer: Research Driven by the Catchment Area of a Cancer CenterEpidemiologic Reviews, 2017
- Five National Cancer Institute–designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trialsCancer, 2014
- A systematic review of the factors influencing African Americans' participation in cancer clinical trialsContemporary Clinical Trials, 2013
- Engaging African American breast cancer survivors in an intervention trial: culture, responsiveness and communityJournal of Cancer Survivorship, 2010
- Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic reviewCancer, 2007